Pilot Window Study: Imatinib Combined with Cetuximab in Head and Neck Squamous Cell Carcinomas

University of Wisconsin – Madison is investigating whether tumor AXL levels correlate with treatment response to imatinib mesilate combined with cetuximab in patients with head and neck squamous cell carcinoma. Conducted in the window between diagnosis and definitive therapy, the study involves research blood draws and biopsies, with a total study duration of approximately 13 to 16 months.